AllergyTalk

A Practical Anaphylaxis Series: Recognize and RespondEpisode 2: Acute Management, Prevention, and the Evolving Landscape
Miniseries Description:
Timely epinephrine use remains central to anaphylaxis management, yet barriers continue to delay treatment. Join host Dr. David Stukus and experts Drs. Syed Shahzad Mustafa and David B.K. Golden as they discuss epinephrine as first-line treatment, the limitations of antihistamines and corticosteroids, and available and emerging epinephrine delivery options. Explore how shared decision-making, patient education, and preparedness can support prompt treatment amid the evolving landscape of anaphylaxis.
Host: David R. Stukus, MD, FACAAI
Guests: Syed Shahzad Mustafa, MD, FACAAI, David B.K. Golden, MD, FACAAI
This episode is eligible for CME credit: Acute Management, Prevention & the Evolving Landscape
This podcast/vodcast miniseries is supported by an independent medical education grant from Aquestive Therapeutics, Inc.
Target Audience:
This activity is intended for Allergists, Advanced Practice Providers, and office staff.
Learning Objectives:
After completing this activity, participants should be better able to:
Explain evidence-based management of anaphylaxis, including the rationale for first-line epinephrine use, barriers to timely treatment, and current U.S. and global epidemiologic trends.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Speaker Disclosures:
David R. Stukus, MD, FACAAIConsultant: Aquestive Therapeutics, GenentechResearcher: DBV Technologies, ARS PharmaceuticalsRoyalties or Patent Beneficiary: Springer Publishing
David B.K. Golden, MD, FACAAIConsultant: ARS Pharmaceuticals, Blueprint Medicine, Genentech, Novartis, Thermo Fisher Scientific, Aquestive, Celldex, Kokua, OrexoSpeaker: ALK, ARS Pharmaceuticals
Syed Shahzad Mustafa, MD, FACAAIResearcher: TakedaSpeaker: ARS Pharmaceuticals, AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi
 

A Practical Anaphylaxis Series: Recognize and RespondPart 1: Pathophysiology, Recognition, and Special Populations
Miniseries Description:
Anaphylaxis can be difficult to recognize, with symptoms that vary across patients and age groups. Join host Dr. David Stukus and experts Drs. Jay A. Lieberman and David B.K. Golden as they explore the mechanisms underlying anaphylaxis, diagnostic criteria, and factors that influence reaction severity. Hear practical insights on recognizing atypical presentations, including reactions without skin findings, and helping patients identify when to act.
Host: David R. Stukus, MD, FACAAI
Guests: Jay A. Lieberman, MD, FACAAI, David B.K. Golden, MD, FACAAI
This episode is eligible for CME credit: Part 1: Pathophysiology, Recognition, and Special Populations 
This podcast/vodcast miniseries is supported by an independent medical education grant from Aquestive Therapeutics, Inc.
Target Audience:
This activity is intended for Allergists, Advanced Practice Providers, and office staff.
Learning Objectives:
After completing this activity, participants should be better able to:
Describe the pathophysiology of anaphylaxis and how epinephrine imparts its physiologic effects.
Apply validated diagnostic criteria to recognize anaphylaxis, including age-specific and rapidly evolving clinical presentations.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Speaker Disclosures
David R. Stukus, MD, FACAAIConsultant: Aquestive Therapeutics, GenentechResearcher: DBV Technologies, ARS PharmaceuticalsRoyalties or Patent Beneficiary: Springer Publishing
David B.K. Golden, MD, FACAAIConsultant: ARS Pharmaceuticals, Blueprint Medicine, Genentech, Novartis, Thermo Fisher Scientific, Aquestive, Celldex, Kokua, OrexoSpeaker: ALK, ARS Pharmaceuticals
Jay A. Lieberman, MD, FACAAIAdvisor: Aquestive Therapeutics, DBV Technologies, Genentech, Kaleo PharmaceuticalConsultant: Aquestive Therapeutics, ARS PharmaceuticalsIndependent contractor: AbbVie, Amgen, Celldex Therapeutics, DBV Technologies

Today we are joined by Dr. Vivian Hernandez-Trujillo, the Division Director of Allergy/Immunology at Nicklaus Children’s Hospital, a Clinical Professor of Pediatrics at the Herbert Wertheim School of Medicine, and an assistant editor of Allergy Watch. We will be reviewing the May/June 2026 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 
For those currently listening to the audio version, we are now releasing video versions of AllergyTalk as well! Please visit the ACAAI YouTube channel at https://www.youtube.com/allergists
For information about CME credit, head over to http://education.acaai.org/allergytalk
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
HPV vaccination is associated with lower risk of cancers among females.
Association of muscle instability and long-term prophylaxis in hereditary angioedema.
Prime Editing for p47(phox)-Deficient Chronic Granulomatous Disease.
Recent article on TriNetX studies: https://www.science.org/content/article/medical-students-are-using-popular-research-tool-pump-out-misleading-studies 
NYTimes article discussing the economics of gene therapy for rare diseases: https://www.nytimes.com/2025/09/22/health/gene-editing-rare-diseases-fda.html
Please rate our podcast on Apple Podcasts and YouTube!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today we are joined by Dr. Vivian Hernandez-Trujillo, the Division Director of Allergy/Immunology at Nickalus Children’s Hospital, a Clinical Professor of Pediatrics at the Herbert Wertheim School of Medicine, and an assistant editor of Allergy Watch. We will be reviewing the May/June 2026 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 
For those currently listening to the audio version, we are now releasing video versions of AllergyTalk as well! Please visit the ACAAI YouTube channel at https://www.youtube.com/allergists
For information about CME credit, head over to http://education.acaai.org/allergytalk
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Identifying gaps: A survey of food allergy knowledge and management in US adults.
Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation.
Fresh clothes, hard breaths: Laundry washing habits, detergents, softeners, and impaired respiratory functions in children with wheezing.
NIH calculator: https://bst-calculater.niaid.nih.gov
Please rate our podcast on Apple Podcasts and YouTube!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today we are joined by Dr. Sarah Spriet, a Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia and an assistant editor of Allergy Watch. We will be reviewing the January/February 2026 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 
For those currently listening to the audio version, we are now releasing video versions of AllergyTalk as well! Please visit the ACAAI YouTube channel at https://www.youtube.com/allergists
For information about CME credit, head over to http://education.acaai.org/allergytalk
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial.
Stock Inhalers in Chicago Public Schools: Using the RE-AIM Framework to Assess Impact.
Type 2 cytokines pleiotropically modulate sensory nerve architecture and neuroimmune interactions to mediate itch.

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology. For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Today we joined by Dr. Sarah, Spriet, a Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia and an assistant editor of Allergy Watch. We will be reviewing the January/February 2026 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODYmolecule.
Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis
Food allergy clinical course in children and adolescents treated with dupilumab for atopic dermatitis.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology. For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Today we joined by Dr. Shyam Joshi, an associate professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch! We will be reviewing the November-December 2025 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Food-Induced Anaphylaxis: Data From the European Anaphylaxis Registry
Introduction of allergenic foods after treatment with omalizumab
Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today we joined by Dr. Shyam Joshi, an associate professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch! We will be reviewing the November-December 2025 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
And for those currently listening to the audio version, we are now releasing a video versions of AllergyTalk! Please visit the ACAAI YouTube channel at https://www.youtube.com/@allergists
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Paging ChatGPT: Potential and Limitations: Can ChatGPT provide parent education for oral immunotherapy? 
2024 Consensus Report: A New Consensus Definition for Anaphylaxis: Anaphylaxis definition, overview, and clinical support tool: 2024 consensus report-a GA(2)LEN project. 
Zileuton Prevents Food Allergen Induced Anaphylaxis in Mice: Cysteinyl leukotrienes stimulate gut absorption of food allergens to promote anaphylaxis in mice.
Please rate our podcast on Apple Podcasts or YouTube!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Part 3: Biologics in IgE-Mediated Food Allergy: Expanding the Toolbox This episode examines the growing role of biologic therapies like omalizumab in managing complex food allergies, reviewing trial data, mechanisms, and practical guidance for collaborative care.
Host Gerald Lee, MD, FACAAI, is joined by Brian P. Vickery, MD, Professor of Pediatrics, Marcus Professor of Pediatric Immunology, and Chief of the Division of Allergy/Immunology at Emory University and Children’s Healthcare of Atlanta, and Julie Wang, MD, FACAAI, Professor of Pediatrics in the Division of Allergy and Immunology at the Icahn School of Medicine at Mount Sinai.
For more information on this topic, please visit:
Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332
Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034
Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918
Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014
Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
This podcast miniseries is supported by Genentech.

Part 2: Immunotherapy for IgE-Mediated Food Allergy: OIT, SLIT & EPIT This episode explores FDA-approved and emerging immunotherapies for food allergy—OIT, SLIT, and EPIT—highlighting their indications, efficacy, safety, and role in shared decision-making.
Host Gerald Lee, MD, FACAAI, is joined by Edwin H. Kim, MD, FACAAI, Associate Professor of Pediatrics and Chief of the Division of Pediatric Allergy and Immunology at the University of North Carolina School of Medicine and Julie Wang, MD, FACAAI, Professor of Pediatrics in the Division of Allergy and Immunology at the Icahn School of Medicine at Mount Sinai.
For more information on this topic, please visit:
Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332
Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034
Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918
Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014
Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
This podcast miniseries is supported by Genentech.